Researchers from the U.K. have investigated the specificity and sensitivity of clonidine growth hormone (GH) as a biomarker for the differential diagnosis of multiple system atrophy (MSA) from pure autonomic failure (PAF), Parkinson’s disease (PD) and progressive supranuclear palsy (PSP).